 |
|
|
| |
Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection on stable nucleos(t)ide analogue therapy: interim results from the randomised Phase 2b B-Clear study
|
| |
| |
EASL 2022 June 22-26 London
Yuen M-F1, Plesniak R2, Lim S-G3, Tsuji K4, Diaconescu G5, Gadano A6, Kim JH7, Asselah T8, Yim HJ9, Heo J10, Rizzardini G11, Janssen HLA12,13, Popescu CP14, Petrova D15, Wong A16, Idriz N17, Pojoga C18,19, Tanaka Y20, Gusev D21, Fzewska E22, Cremer J23, Elston R24, Lukic T25, Maynard L24, Kendrick S24, Bharania P26, Campbell F24, Paff M27, Theodore D23 on behalf of the B-Clear Study Group
EASL: Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection: interim results from the randomised Phase 2b B-Clear study - (06/26/22)
|
| |
|
|
|
|
|
